11,989 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by ING Groep NV

ING Groep NV purchased a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 11,989 shares of the pharmaceutical company’s stock, valued at approximately $4,695,000.

Several other institutional investors have also recently made changes to their positions in the stock. Chesapeake Asset Management LLC grew its stake in shares of Vertex Pharmaceuticals by 110.0% in the third quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock valued at $25,000 after buying an additional 33 shares in the last quarter. Access Investment Management LLC acquired a new stake in Vertex Pharmaceuticals in the second quarter valued at $27,000. Legacy Investment Solutions LLC acquired a new stake in Vertex Pharmaceuticals in the second quarter valued at $29,000. Total Investment Management Inc. bought a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $33,000. Finally, Financial Network Wealth Advisors LLC increased its stake in shares of Vertex Pharmaceuticals by 50.9% during the 3rd quarter. Financial Network Wealth Advisors LLC now owns 86 shares of the pharmaceutical company’s stock worth $34,000 after purchasing an additional 29 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on VRTX shares. Evercore raised their target price on shares of Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Sanford C. Bernstein raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, January 12th. Weiss Ratings raised Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, February 4th. Scotiabank assumed coverage on Vertex Pharmaceuticals in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $495.00 price target on the stock. Finally, Royal Bank Of Canada raised shares of Vertex Pharmaceuticals from a “sector perform” rating to an “outperform” rating and lifted their price objective for the stock from $455.00 to $546.00 in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $522.68.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Revenue and product momentum: Vertex reported quarter-over-quarter revenue growth (total revenue ~$3.19B, ~+9.5% YoY), which some outlets framed as a revenue beat or in-line with estimates — supporting confidence in core cystic fibrosis franchises. Vertex Q4 Revenue Beats
• Positive Sentiment: Pipeline expansion: Vertex announced a partnership with WuXi to broaden its autoimmune pipeline beyond cystic fibrosis, which could diversify future revenue streams and reduce single-therapy concentration risk. Partnership with WuXi
• Neutral Sentiment: 2026 guidance broadly in-line: Management gave revenue guidance centered around ~$13.0–13.1B, which Reuters and the company describe as roughly matching analysts’ expectations; this limits downside from guidance but doesn’t materially raise the bar. Reuters: Guidance In-Line
• Neutral Sentiment: Analyst sentiment and valuation context: Multiple analysts maintain bullish ratings and above-consensus price targets (median targets well above current levels), supporting longer-term upside; valuation and momentum write-ups are circulating for investors weighing entry timing. Zacks: Momentum Thesis
• Negative Sentiment: Small EPS miss and mixed beats: EPS came in marginally below consensus (reported ~$5.03 vs. estimates near $5.05–$5.07), and some data feeds showed revenue slightly under certain Street models — a near-term driver for the post-release price pullback among short-term traders. Zacks: EPS Miss Zacks: Metric Comparison
• Negative Sentiment: Insider selling: Multiple senior executives disclosed stock sales (several EVPs and the CAO among them), and trackers note a pattern of insider liquidations over recent months — this raises short-term sentiment risk even if sales are routine diversification. Quiver: Insider Selling and Earnings Reaction

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 466 shares of the business’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $460.43, for a total value of $214,560.38. Following the completion of the sale, the executive vice president owned 51,436 shares of the company’s stock, valued at $23,682,677.48. The trade was a 0.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Edward Morrow Atkinson III sold 1,751 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total transaction of $806,212.93. Following the transaction, the executive vice president directly owned 22,046 shares in the company, valued at $10,150,639.78. This represents a 7.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 99,352 shares of company stock worth $45,037,314. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Price Performance

VRTX opened at $465.02 on Friday. The business has a fifty day simple moving average of $459.26 and a 200 day simple moving average of $427.55. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.68. The company has a market capitalization of $117.98 billion, a PE ratio of 32.79 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 23.51% and a net margin of 31.35%.The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the business posted $3.98 EPS. Equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.